JERUSALEM and NEEDHAM, Massachusetts, June 17 /PRNewswire-FirstCall/ -- Oridion Systems Ltd. - (SWX: ORIDN) Significant findings from numerous medical research projects demonstrating the clinical benefit of end-tidal CO2 (EtCO2) monitoring using Microstream(R) capnography technology, were recently presented at medical congresses in the United States and Europe.
During Digestive Disease Week (DDW) in San Diego, California, Dr. Vargo, of the Cleveland Clinic, presented a blinded study that analyzed 122 randomized patients and showed that Microstream(R) capnography "significantly reduces the proportion of patients with hypoxemia, major hypoxemia, apnea and oxygen requirements during ERCP (Endoscopic Retrograde Cholangiopancreatography) and EUS (Endoscopic ultrasound).
Other studies describing the clinical value of Microstream(R) EtCO2 monitoring were presented during the European Resuscitation Council (ERC) in Ghent, Belgium and the European Society of Anesthesiology (ESA) in Copenhagen, Denmark. At ERC, two oral presentations were given and a Capnography Symposium took place with three distinguished clinicians and the clinical practice manager from London Ambulance Service. The four presentations showed the value of capnography in pre-hospital care (trauma, intubations, and ROSC). The Symposium was moderated by Prof. Pierre Carli, President Societe Francaise d'Anesthesie et de Reanimation (French Society of Anesthesia and Intensive Care).
Two medical presentations given at European Society of Anesthesia demonstrated the importance of capnography for non-intubated and intubated patients. In a study on the use of continuous non-invasive arterial CO2 estimation in spontaneously breathing patients after craniotomy, Dr. Wolter from France showed a good correlation between capnography and arterial blood gas analysis in sedated patients under regional anesthesia.
"These recent studies continue to confirm that patients are safer when their caregivers use Oridion Microstream(R) capnography technology," stated Gerry Feldman, President of Oridion Capnography. "The results of these global research projects clearly demonstrate that capnography improves patient safety and should be included in hospital and pre-hospital ventilatory monitoring strategies."
Oridion is the global leader of innovative capnography monitoring solutions helping to improve patient safety, and its Microstream(R) capnography technology has become the standard of care in ventilation monitoring.
A full list of these medical abstracts can be found on the Oridion
Next financial reporting:
August 18, 2008 Results Q2 / Half Year 2008
November 10, 2008 Results Q3 / Nine Months 2008
About Oridion Oridion Systems Ltd. (http://www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel.
Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream(R) technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.
Certain statements made herein that are not historical are
forward-looking. The words "estimate" "project" "intend" "expect" "believe"
and similar expressions are intended to identify forward-looking
statements. These forward-looking statements involve known and unknown
risks and uncertainties. Many factors could cause the actual results,
performance or achievements of the Company to be materially different from
any future results, performance or achievements that may be expressed or
implied by such forward-looking statements, including, among others, our
ability to maintain profits, the market demands for our Capnography
products, our ability to focus our team on the Capnography business,
changes in general economic and business conditions, inability to maintain
market acceptance to the Company's products, inability to timely develop
and introduce new technologies, products and applications, rapid changes in
the market for the Company's products, loss of market share and pressure on
prices resulting from competition, introduction of competing products by
other companies, inability to manage growth and expansion, loss of key OEM
partners, factors effecting OEM partners' position in the market, inability
to attract and retain qualified personnel, inability to protect the
Company's proprietary technology.
For further information please contact:
Alan Adler, Chairman and Chief Executive Officer
Gerry Feldman, President
Walter Tabachnik, Chief Financial Officer
Elena Gerberg, Investor Relations
website : http://www.oridion.com
phone : +972-2-589-9159
address : Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel
|SOURCE Oridion Systems Ltd.|
Copyright©2008 PR Newswire.
All rights reserved